BR9506667A - Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanol - Google Patents
Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanolInfo
- Publication number
- BR9506667A BR9506667A BR9506667A BR9506667A BR9506667A BR 9506667 A BR9506667 A BR 9506667A BR 9506667 A BR9506667 A BR 9506667A BR 9506667 A BR9506667 A BR 9506667A BR 9506667 A BR9506667 A BR 9506667A
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- pyrimidine
- diamino
- cyclo
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Indole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Liquid Crystal Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9402161A GB9402161D0 (en) | 1994-02-04 | 1994-02-04 | Chloropyrimidine intermediates |
PCT/GB1995/000225 WO1995021161A1 (en) | 1994-02-04 | 1995-02-03 | Chloropyrimide intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9506667A true BR9506667A (pt) | 1997-09-16 |
Family
ID=10749873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9506667A BR9506667A (pt) | 1994-02-04 | 1995-02-03 | Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanol |
Country Status (28)
Country | Link |
---|---|
US (8) | US6448403B1 (pt) |
EP (1) | EP0741710B1 (pt) |
JP (1) | JP3670012B2 (pt) |
KR (1) | KR100355983B1 (pt) |
CN (2) | CN1105109C (pt) |
AT (1) | ATE192742T1 (pt) |
AU (1) | AU690203B2 (pt) |
BR (1) | BR9506667A (pt) |
DE (1) | DE69516847T2 (pt) |
DK (1) | DK0741710T3 (pt) |
ES (1) | ES2148486T3 (pt) |
FI (1) | FI112477B (pt) |
GB (1) | GB9402161D0 (pt) |
GR (1) | GR3033850T3 (pt) |
HK (1) | HK1004087A1 (pt) |
HU (1) | HU223096B1 (pt) |
IL (1) | IL112539A (pt) |
MX (1) | MX9603091A (pt) |
MY (1) | MY113775A (pt) |
NO (1) | NO310819B1 (pt) |
NZ (1) | NZ278948A (pt) |
PL (1) | PL183885B1 (pt) |
PT (1) | PT741710E (pt) |
RU (1) | RU2140913C1 (pt) |
SG (1) | SG47918A1 (pt) |
TW (1) | TW390877B (pt) |
WO (1) | WO1995021161A1 (pt) |
ZA (1) | ZA95884B (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9402161D0 (en) * | 1994-02-04 | 1994-03-30 | Wellcome Found | Chloropyrimidine intermediates |
CA2145928C (en) * | 1994-04-27 | 2007-10-09 | Gerhard Stucky | N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation |
SK285229B6 (sk) * | 1997-05-13 | 2006-09-07 | Lonza Ag | Spôsob výroby derivátov (1R,4S)- alebo (1S,4R)-1-amino-4- (hydroxymetyl)-2-cyklopenténu a enantioméru (1R,4S)-N-butyryl-1- amino-4-(hydroxymetyl)-2-cyklopenténu |
GB9721780D0 (en) * | 1997-10-14 | 1997-12-10 | Glaxo Group Ltd | Process for the synthesis of chloropurine intermediates |
AU2702899A (en) * | 1997-10-24 | 1999-05-17 | Glaxo Group Limited | Process for preparing a chiral nucleoside analogue |
WO1999024431A1 (en) * | 1997-11-12 | 1999-05-20 | Glaxo Group Limited | Process for preparing a chiral nucleoside analogue |
SK284595B6 (sk) | 1997-11-27 | 2005-07-01 | Lonza Ag | Spôsob výroby (1S,4R)-4-(2-amino-6-chlór-9H-purín-9-yl)-2- cyklopentén-1-metanolu alebo jeho solí |
ES2204798T3 (es) * | 1998-12-21 | 2004-05-01 | Lonza Ag | Procedimiento para la preparacion de 2,5-diamino-4,6-dihalogenopirimidina. |
WO2002069900A2 (en) * | 2001-03-01 | 2002-09-12 | Conforma Therapeutics Corp. | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
EP2336133A1 (en) * | 2001-10-30 | 2011-06-22 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
US6780635B2 (en) | 2001-12-27 | 2004-08-24 | Council Of Scientific And Industrial Research | Process for the preparation of optically active azabicyclo heptanone derivatives |
KR100573859B1 (ko) * | 2002-07-15 | 2006-04-25 | 경동제약 주식회사 | 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의제조방법 |
US7560231B2 (en) * | 2002-12-20 | 2009-07-14 | Roche Molecular Systems, Inc. | Mannitol and glucitol derivatives |
US20040266795A1 (en) * | 2003-04-30 | 2004-12-30 | Genny Shamai | Process for the preparation of famciclovir |
JPWO2004103979A1 (ja) * | 2003-05-26 | 2006-07-20 | 住友化学株式会社 | N−(2−アミノ−4,6−ジクロロピリミジン−5−イル)ホルムアミドの製造方法 |
KR100573860B1 (ko) * | 2003-06-13 | 2006-04-25 | 경동제약 주식회사 | 2-아미노-9-(2-치환에틸)푸린을 이용한 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의 제조방법 |
US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
KR100573861B1 (ko) * | 2003-07-18 | 2006-04-25 | 경동제약 주식회사 | 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법 |
GB0320738D0 (en) | 2003-09-04 | 2003-10-08 | Glaxo Group Ltd | Novel process |
EP1556383A1 (en) * | 2003-09-04 | 2005-07-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing famciclovir |
EA010160B1 (ru) | 2003-09-18 | 2008-06-30 | Конформа Терапьютикс Корпорейшн | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения |
DE102004002055A1 (de) * | 2004-01-15 | 2005-08-11 | Degussa Ag | Verfahren zur Herstellung von 2-Amino-4,6-dichlor-5-formamidopyrimidin |
MX2007002043A (es) * | 2004-08-16 | 2007-10-11 | Quark Biotech Inc | Usos terapeuticos de los inhibidores del rtp801. |
NZ561939A (en) * | 2005-03-30 | 2011-03-31 | Conforma Therapeutics Corp | Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors |
GB2426247A (en) | 2005-05-20 | 2006-11-22 | Arrow Int Ltd | Methods of preparing purine derivatives such as famciclovir |
EP1937258A2 (en) * | 2005-09-23 | 2008-07-02 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
EP1857458A1 (en) * | 2006-05-05 | 2007-11-21 | SOLMAG S.p.A. | Process for the preparation of abacavir |
CN100465174C (zh) * | 2006-06-13 | 2009-03-04 | 中国科学院上海有机化学研究所 | 制备光学纯阿巴卡韦的方法 |
WO2008072074A1 (en) * | 2006-12-11 | 2008-06-19 | Aurobindo Pharma Limited | An improved process for the preparation of purine derivative |
EP1939196A1 (en) * | 2006-12-21 | 2008-07-02 | Esteve Quimica, S.A. | Process for the preparation of abacavir |
EP2170840A1 (en) * | 2007-06-21 | 2010-04-07 | Aurobindo Pharma Ltd | An improved process for preparing purine derivative |
EP2085397A1 (en) | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
AU2011209788C1 (en) | 2010-01-27 | 2014-08-28 | Viiv Healthcare Company | Antiviral therapy |
CZ305457B6 (cs) * | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
US9457028B2 (en) | 2013-02-27 | 2016-10-04 | Kyoto University | Pharmaceutical composition for use in prevention or treatment of cancer |
CN104672239A (zh) * | 2013-11-26 | 2015-06-03 | 上海迪赛诺化学制药有限公司 | 一种采用一锅法制备阿巴卡韦式v中间体的工艺 |
CN109456329B (zh) * | 2018-11-19 | 2021-03-09 | 迪嘉药业集团有限公司 | 一种泛昔洛韦的制备方法 |
CN113292507B (zh) * | 2021-06-25 | 2022-07-19 | 潍坊奥通药业有限公司 | 一种2-氨基-6-氯鸟嘌呤及其中间体的制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3485225D1 (de) | 1983-08-18 | 1991-12-05 | Beecham Group Plc | Antivirale guanin-derivate. |
DE3582399D1 (de) | 1984-09-20 | 1991-05-08 | Beecham Group Plc | Purin-derivate und ihre pharmazeutische verwendung. |
US4965270A (en) | 1987-05-30 | 1990-10-23 | Beecham Group P.L.C. | Purine derivatives |
GB8724765D0 (en) | 1987-10-22 | 1987-11-25 | Beecham Group Plc | Process |
US4916224A (en) | 1988-01-20 | 1990-04-10 | Regents Of The University Of Minnesota | Dideoxycarbocyclic nucleosides |
GB2243609B (en) * | 1988-01-20 | 1992-03-11 | Univ Minnesota | Dideoxydidehydrocarbocyclic pyrimidines |
US5631370A (en) | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
GB8916698D0 (en) | 1989-07-21 | 1989-09-06 | Beecham Group Plc | Novel process |
GB8918827D0 (en) | 1989-08-17 | 1989-09-27 | Beecham Group Plc | Novel compounds |
MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
CZ287049B6 (cs) * | 1992-01-22 | 2000-08-16 | Lonza A. G. | N-5-chráněné 2,5-diamino-4,6-dichlorpyrimidiny a způsob jejich přípravy |
GB9402161D0 (en) * | 1994-02-04 | 1994-03-30 | Wellcome Found | Chloropyrimidine intermediates |
CA2145928C (en) | 1994-04-27 | 2007-10-09 | Gerhard Stucky | N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation |
-
1994
- 1994-02-04 GB GB9402161A patent/GB9402161D0/en active Pending
-
1995
- 1995-02-03 NZ NZ278948A patent/NZ278948A/en not_active IP Right Cessation
- 1995-02-03 DE DE69516847T patent/DE69516847T2/de not_active Expired - Lifetime
- 1995-02-03 AT AT95907107T patent/ATE192742T1/de active
- 1995-02-03 ZA ZA95884A patent/ZA95884B/xx unknown
- 1995-02-03 US US08/682,743 patent/US6448403B1/en not_active Expired - Lifetime
- 1995-02-03 ES ES95907107T patent/ES2148486T3/es not_active Expired - Lifetime
- 1995-02-03 IL IL11253995A patent/IL112539A/xx not_active IP Right Cessation
- 1995-02-03 PT PT95907107T patent/PT741710E/pt unknown
- 1995-02-03 MY MYPI95000246A patent/MY113775A/en unknown
- 1995-02-03 KR KR1019960704228A patent/KR100355983B1/ko not_active IP Right Cessation
- 1995-02-03 PL PL95315713A patent/PL183885B1/pl unknown
- 1995-02-03 CN CN95191478A patent/CN1105109C/zh not_active Expired - Lifetime
- 1995-02-03 BR BR9506667A patent/BR9506667A/pt not_active IP Right Cessation
- 1995-02-03 SG SG1996005343A patent/SG47918A1/en unknown
- 1995-02-03 HU HU9602114A patent/HU223096B1/hu active IP Right Grant
- 1995-02-03 RU RU96118435A patent/RU2140913C1/ru active
- 1995-02-03 AU AU15438/95A patent/AU690203B2/en not_active Expired
- 1995-02-03 EP EP95907107A patent/EP0741710B1/en not_active Expired - Lifetime
- 1995-02-03 WO PCT/GB1995/000225 patent/WO1995021161A1/en active IP Right Grant
- 1995-02-03 CN CNB021023441A patent/CN1161343C/zh not_active Expired - Lifetime
- 1995-02-03 DK DK95907107T patent/DK0741710T3/da active
- 1995-02-03 JP JP52046795A patent/JP3670012B2/ja not_active Expired - Lifetime
- 1995-03-14 TW TW084102412A patent/TW390877B/zh not_active IP Right Cessation
-
1996
- 1996-07-30 MX MX9603091A patent/MX9603091A/es unknown
- 1996-08-02 NO NO19963239A patent/NO310819B1/no not_active IP Right Cessation
- 1996-08-02 FI FI963070A patent/FI112477B/fi not_active IP Right Cessation
-
1997
- 1997-10-24 US US08/957,606 patent/US6555687B1/en not_active Expired - Lifetime
- 1997-10-24 US US08/957,605 patent/US5917042A/en not_active Expired - Lifetime
- 1997-10-24 US US08/957,043 patent/US5917041A/en not_active Expired - Lifetime
- 1997-10-24 US US08/957,603 patent/US6087501A/en not_active Expired - Lifetime
-
1998
- 1998-04-21 HK HK98103336A patent/HK1004087A1/xx not_active IP Right Cessation
-
1999
- 1999-10-15 US US09/419,416 patent/US6552193B1/en not_active Expired - Lifetime
-
2000
- 2000-06-30 GR GR20000401551T patent/GR3033850T3/el unknown
-
2002
- 2002-06-27 US US10/184,482 patent/US6870053B2/en not_active Expired - Fee Related
-
2003
- 2003-03-18 US US10/389,815 patent/US20030187263A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9506667A (pt) | Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanol | |
ATE245646T1 (de) | Therapeutische nukleoside | |
ES2149157T3 (es) | Nuevo procedimiento para la preparacion de nucleotidos. | |
EA199900279A1 (ru) | Производные бензамида и их применение в качестве лекарственных средств с лтв4-антагонистической активностью | |
BR9808923A (pt) | Composto, e, processo para fazer o mesmo | |
BR9811855A (pt) | Processo para preparação de ácido l-ascórbico | |
BR0011996A (pt) | Preparação de piperidin-4-onas substituìdas | |
CA2227762A1 (en) | Substituted aminouracils | |
IT1293777B1 (it) | Processo per la preparazione di tetraazamacrocicli | |
ES2169053T3 (es) | Compuestos intermedios en la sintesis de cefalosporinas. | |
BR9807785A (pt) | Processo para a preparação do composto, e, composto | |
BR9607850A (pt) | Processo para a preparação de um composto e composto | |
DE69418050D1 (de) | Antivirale analoge von difluorostaton | |
ES2152982T3 (es) | Analogos de la difluoroestatona. | |
BR9906931A (pt) | Triazepinonas, processo para sua preparação e sua aplicação terapêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
FF | Decision: intention to grant | ||
FG9A | Patent or certificate of addition granted | ||
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 03/02/2015 |